做经动脉化疗栓塞术还是不做？来自一项阴性试验的经验教训。 - Suppr | 超能文献

To TACE or not to TACE? Lessons from a negative trial.

作者信息

Raoul Jean-Luc, Gilabert Marine, Adhoute Xavier

机构信息

Department of Medical Oncology, Paoli-Calmettes Institute, 13273 Marseille, France.

Department of Medical Oncology, Paoli-Calmettes Institute, 13273 Marseille, France.

出版信息

Lancet Gastroenterol Hepatol. 2017 Aug;2(8):541-543. doi: 10.1016/S2468-1253(17)30181-4. Epub 2017 Jun 23.

DOI:10.1016/S2468-1253(17)30181-4

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

To TACE or not to TACE? Lessons from a negative trial.做经动脉化疗栓塞术还是不做？来自一项阴性试验的经验教训。

Lancet Gastroenterol Hepatol. 2017 Aug;2(8):541-543. doi: 10.1016/S2468-1253(17)30181-4. Epub 2017 Jun 23.

2

Chemoembolization combined with radiofrequency ablation for patients with hepatocellular carcinoma larger than 3 cm: a randomized controlled trial.经动脉化疗栓塞联合射频消融治疗直径大于3cm的肝细胞癌患者：一项随机对照试验

JAMA. 2008 Apr 9;299(14):1669-77. doi: 10.1001/jama.299.14.1669.

3

Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy.巨大原发性肝细胞癌：单纯经动脉化疗栓塞治疗与联合经动脉化疗栓塞-经皮微波凝固治疗的比较。

J Gastroenterol Hepatol. 2013 Mar;28(3):456-63. doi: 10.1111/jgh.12088.

4

Transcatheter arterial chemoembolization combined with radiofrequency ablation for the treatment of hepatocellular carcinoma.经导管动脉化疗栓塞联合射频消融治疗肝细胞癌。

Oncology. 2013;84 Suppl 1:40-3. doi: 10.1159/000345888. Epub 2013 Feb 20.

5

Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone.中等大小（3.1-5.0 厘米）肝细胞癌：经动脉化疗栓塞联合射频消融与单纯射频消融的比较。

Ann Surg Oncol. 2011 Jun;18(6):1624-9. doi: 10.1245/s10434-011-1673-8. Epub 2011 Mar 29.

6

Anti-angiogenic therapy in the setting of TACE: an elusive synergy?经动脉化疗栓塞（TACE）背景下的抗血管生成治疗：一种难以捉摸的协同作用？

Lancet Gastroenterol Hepatol. 2018 Jan;3(1):5-6. doi: 10.1016/S2468-1253(17)30324-2. Epub 2017 Oct 4.

7

Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.与经动脉化疗栓塞术或索拉非尼相比，肝切除术治疗伴有门静脉癌栓的肝细胞癌的生存结局。

Clin Mol Hepatol. 2016 Mar;22(1):160-7. doi: 10.3350/cmh.2016.22.1.160. Epub 2016 Mar 28.

8

Systematic review of neoadjuvant transarterial chemoembolization for resectable hepatocellular carcinoma.系统评价新辅助经动脉化疗栓塞治疗可切除肝细胞癌。

Liver Int. 2010 Feb;30(2):166-74. doi: 10.1111/j.1478-3231.2009.02166.x. Epub 2009 Nov 13.

9

Meta-analysis of transcatheter arterial chemoembolization plus radiofrequency ablation versus transcatheter arterial chemoembolization alone for hepatocellular carcinoma.经动脉化疗栓塞联合射频消融与单纯经动脉化疗栓塞治疗肝细胞癌的Meta分析

Oncotarget. 2017 Jan 10;8(2):2960-2970. doi: 10.18632/oncotarget.13813.

10

Patterns of sorafenib and TACE treatment of unresectable hepatocellular carcinoma in a Chinese population: subgroup analysis of the GIDEON study.索拉非尼与经动脉化疗栓塞术治疗中国人群不可切除肝细胞癌的模式：GIDEON研究的亚组分析

Mol Biol Rep. 2017 Feb;44(1):149-158. doi: 10.1007/s11033-016-4092-x. Epub 2016 Dec 15.

引用本文的文献

1

Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: a systematic review and meta-analysis.PD-1/PD-L1抑制剂治疗晚期肝细胞癌患者的临床结局：一项系统评价和荟萃分析。

J Cancer Res Clin Oncol. 2023 Mar;149(3):969-978. doi: 10.1007/s00432-022-04057-3. Epub 2022 Jun 30.

2

Clinical outcomes and influencing factors of PD-1/PD-L1 in hepatocellular carcinoma.肝细胞癌中PD-1/PD-L1的临床结局及影响因素

Oncol Lett. 2021 Apr;21(4):279. doi: 10.3892/ol.2021.12540. Epub 2021 Feb 10.